Cimerli Alternatives Compared
| Cimerli (ranibizumab) | Vabysmo (faricimab) | Syfovre (pegcetacoplan) |
|
|---|
| Cimerli (ranibizumab) | Vabysmo (faricimab) | Syfovre (pegcetacoplan) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Macular Degeneration, Diabetic Macular Edema, Macular Edema Following Retinal Vein Occlusion , Macular Edema, Diabetic Retinopathy, Myopic Choroidal Neovascularization. Cimerli may... View more |
Prescription only
Prescribed for Macular Degeneration, Macular Edema Following Retinal Vein Occlusion , Diabetic Macular Edema, Macular Edema. Vabysmo may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Macular Degeneration, Geographic Atrophy. Syfovre may also be used for purposes not listed in this medication guide. |
Related suggestions Macular Degeneration
|
|||||||||||||||||||||||
| More about Cimerli (ranibizumab) | More about Vabysmo (faricimab) | More about Syfovre (pegcetacoplan) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Be the first to share your experience with this drug. |
Vabysmo has an average rating of 7.9 out of 10 from a total of 26 ratings on Drugs.com. 65% of reviewers reported a positive effect, while 8% reported a negative effect. |
Syfovre has an average rating of 9.3 out of 10 from a total of 4 ratings on Drugs.com. 75% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Cimerli prices |
View all Vabysmo prices |
View all Syfovre prices |
||||||||||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other ranibizumab brands include: Byooviz, Lucentis, Susvimo |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
216 hours |
180 hours |
108 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 1 drugs are known to interact with Cimerli:
|
No known drug interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
A total of 2 drugs are known to interact with Syfovre:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
January 28, 2022 |
N/A |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.